Arcutis Biotherapeutics, Inc. 4

Non-employee director Christopher Peetz received RSU and stock option awards in Arcutis Biotherapeutics, Inc. common stock on July 15, 2026 as part of his director compensation.

On July 15, 2026, non-employee director Christopher Peetz of Arcutis Biotherapeutics, Inc. received an equity compensation package consisting of 4,315 restricted stock units (RSUs) of common stock and two stock option grants with an exercise price of $27.78 per share for 21,486 shares and 13,010 shares, respectively. The RSUs, which convert into one share of common stock per unit, will vest on the earlier of June 5, 2027 or immediately prior to the next annual meeting of stockholders, contingent on his continued board service. One option grant for 21,486 shares vests 100% on the earlier of June 5, 2027 or immediately before the next annual meeting, while the other option grant for 13,010 shares vests in thirds annually starting July 15, 2027 and becomes fully vested on the fourth anniversary of the July 15, 2026 vesting commencement date. Following these awards, Peetz holds 4,315 deferred common shares directly via RSUs and 34,496 option shares subject to vesting, while 187,500 additional common shares are held indirectly by The Peetz Family Trust, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Filing Facts

CIK

1787306

Ticker

ARQT

Form

4

Source Type

fda

Accession

0001628280-26-048655

Alert Tier

5